Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 30, 2022 06:50 ET | Source: Pharvaris N.V.

Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer

ZUG, Switzerland, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
September 16, 2022 04:45 ET | Source: Pharvaris N.V.

Pharvaris Highlights Data Supporting Clinical Development Program for Hereditary Angioedema at the 2022 Bradykinin Symposium

ZUG, Switzerland, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
September 12, 2022 06:50 ET | Source: Pharvaris N.V.

Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update

Formal letters received from FDA relating to the previously announced hold on clinical studies of PHA121 in the U.S.Top-line data anticipated in 4Q22 for RAPIDe-1, a global Phase 2 study of PHVS416...
August 22, 2022 06:50 ET | Source: Pharvaris N.V.

Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S.

ZUG, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
July 14, 2022 08:10 ET | Source: Pharvaris N.V.

Pharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference

ZUG, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks,...
July 06, 2022 08:10 ET | Source: Pharvaris N.V.

Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13

ZUG, Switzerland, July 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks,...
June 14, 2022 08:10 ET | Source: Pharvaris N.V.

Pharvaris Announces Annual Meeting of Shareholders

ZUG, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks,...
June 07, 2022 08:10 ET | Source: Pharvaris N.V.

Pharvaris Participates in the Kinin 2022 Conference

ZUG, Switzerland, June 07, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks,...
May 16, 2022 08:10 ET | Source: Pharvaris N.V.

Pharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day :-)

ZUG, Switzerland, May 16, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks,...
May 11, 2022 08:15 ET | Source: Pharvaris N.V.

Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer

Pharvaris’ executive team further strengthened by Ms. Schmidt’s deep international experience and biopharmaceutical industry tenure ZUG, Switzerland, May 11, 2022 (GLOBE NEWSWIRE) -- Pharvaris...